Liou Jyh-Ming, Malfertheiner Peter, Hong Tzu-Chan, Cheng Hsiu-Chi, Sugano Kentaro, Shah Shailja, Sheu Bor-Shyang, Chen Mei-Jyh, Chiang Tsung-Hsien, Chen Yi-Chu, Yamaoka Yoshio, Wong Sunny H, Chen Chieh-Chang, Lee Yeong Yeh, Quach Duc Trong, Wu Deng-Chyang, Hsu Ping-I, Wu Chun-Ying, Wu Jeng-Yih, Luo Jiing-Chyuan, Chang Wei-Lun, Lu Hong, Suzuki Hidekazu, Jung Hwoon-Yong, Mahachai Varocha, Vilaichone Ratha-Korn, Mégraud Francis, Lin Jaw-Town, Yeoh Khay-Guan, Leung Wai Keung, El-Omar Emad M, Lee Yi-Chia, Wu Ming-Shiang
Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Gut. 2025 Sep 5. doi: 10.1136/gutjnl-2025-336027.
To convene a global consensus on () screening and eradication strategies for gastric cancer prevention, identify key knowledge gaps and outline future research directions.
32 experts from 12 countries developed and refined consensus statements on management, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess evidence and the Delphi method to achieve ≥80% agreement.
Consensus was achieved on 28 statements. Eradication of , the primary cause of gastric cancer, reduces the risk of gastric cancer across all age groups, with the greatest risk reduction before the onset of premalignant conditions. eradication also promotes ulcer healing, prevents ulcer recurrence and reduces the risk of NSAID/aspirin related ulcers. transmission primarily occurs within families, making family based approaches promising for reducing spread and improving treatment outcomes. screening should prioritise high risk populations. C-urea breath test or monoclonal stool antigen tests are preferred. Validated serological testing is a feasible alternative in low prevalence settings when followed by confirmatory non-serological testing. Integrating screening into existing health programmes may optimise patient adherence and resource utilisation. Empiric eradication treatment, especially bismuth quadruple therapy, is recommended in regions with high antibiotic resistance for conventional antibiotics. Potassium competitive acid blocker based regimens are alternatives. Confirmatory testing is strongly recommended to ensure eradication. Endoscopy is suggested for infected individuals with a high risk of gastric cancer and/or alarm features. eradication does not increase the risk of reflux oesophageal adenocarcinoma. Long term disruptions to the microbiota and resistome, as well as the environmental impact of increased antibiotic use, warrant further investigation. The development of an vaccine remains an unmet need, as does the establishment of a risk stratified approach informed by advanced genetic research.
eradication is an effective prevention strategy for gastric cancer that should be offered to all infected adult individuals. Future research should prioritise determining the optimal timing for screening, evaluating long term individual and population outcomes, as well as identifying more precise risk stratification parameters.
就胃癌预防的(幽门螺杆菌)筛查及根除策略达成全球共识,确定关键知识空白并概述未来研究方向。
来自12个国家的32位专家制定并完善了关于(幽门螺杆菌)管理的共识声明,采用推荐分级评估、制定与评价(GRADE)框架评估证据,并运用德尔菲法达成≥80%的一致意见。
就28项声明达成了共识。根除幽门螺杆菌这一胃癌的主要病因,可降低所有年龄组患胃癌的风险,在癌前病变出现之前风险降低最为显著。根除幽门螺杆菌还可促进溃疡愈合,预防溃疡复发并降低非甾体抗炎药/阿司匹林相关溃疡的风险。幽门螺杆菌传播主要发生在家庭内部,因此基于家庭的方法有望减少传播并改善治疗效果。幽门螺杆菌筛查应优先考虑高危人群。碳-尿素呼气试验或单克隆粪便抗原检测为首选。在低流行地区,经过验证的血清学检测在随后进行确证性非血清学检测时是一种可行的替代方法。将幽门螺杆菌筛查纳入现有卫生项目可优化患者依从性和资源利用。在传统抗生素耐药性高的地区,建议采用经验性根除治疗,尤其是铋剂四联疗法。基于钾竞争性酸阻滞剂的方案为替代方案。强烈建议进行确证性检测以确保幽门螺杆菌根除。对于胃癌风险高和/或有警示特征的幽门螺杆菌感染个体,建议进行内镜检查。根除幽门螺杆菌不会增加反流性食管腺癌的风险。微生物群和耐药组的长期破坏以及抗生素使用增加对环境的影响值得进一步研究。开发幽门螺杆菌疫苗以及建立基于先进基因研究的风险分层方法仍未得到满足。
根除幽门螺杆菌是一种有效的胃癌预防策略,应提供给所有感染的成年个体。未来研究应优先确定筛查的最佳时机,评估长期个体和人群结局,以及确定更精确的风险分层参数。